NCT06497465View on ClinicalTrials.gov

Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 18, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2029

Conditions
TuberculosisHIV
Interventions
DRUG

Dolutegravir 50mg Tab

Participants will receive Dolutegravir 50mg

DRUG

Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]

Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]

DRUG

Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)

Participants will receive Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)

Trial Locations (6)

69040-000

RECRUITING

Instituto Tropical de Doenças Infecciosas Manaus, Manaus

40110-160

RECRUITING

Universidade Federal da Bahia, Salvador

21040-360

RECRUITING

FIOCruz, Rio de Janeiro

26210-190

RECRUITING

Hospital Geral de Nova Iguaçu, Rio de Janeiro

59.025-050

RECRUITING

CePClin - Center for Studies and Research in Infectious Diseases Ltda, Natal

04037-030

RECRUITING

RDSS- Ricardo Diaz Solucoes Cientificas, São Paulo

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Johns Hopkins University

OTHER